USD
$0.00
(0.00%
)At Close (As of Oct 21, 2025)
$2.85M
Market Cap
-
P/E Ratio
-1.62
EPS
$3.62
52 Week High
$0.52
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | -$53K |
Total Revenue | $6.3K |
Cost Of Revenue | $59K |
Costof Goods And Services Sold | $59K |
Operating Income | -$6.2M |
Selling General And Administrative | $4.3M |
Research And Development | $1.8M |
Operating Expenses | $6.1M |
Investment Income Net | - |
Net Interest Income | -$58K |
Interest Income | - |
Interest Expense | $58K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $343K |
Income Before Tax | -$6.2M |
Income Tax Expense | -$137K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$6.1M |
Comprehensive Income Net Of Tax | - |
Ebit | -$6.1M |
Ebitda | -$5.8M |
Net Income | -$6.1M |
Field | Value (USD) |
---|---|
Total Assets | $6.4M |
Total Current Assets | $4.9M |
Cash And Cash Equivalents At Carrying Value | $4.2M |
Cash And Short Term Investments | $4.2M |
Inventory | $95K |
Current Net Receivables | $31K |
Total Non Current Assets | $1.5M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $40K |
Intangible Assets Excluding Goodwill | $40K |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | $94K |
Other Current Assets | $539K |
Other Non Current Assets | - |
Total Liabilities | $965K |
Total Current Liabilities | $673K |
Current Accounts Payable | $56K |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $85K |
Total Non Current Liabilities | $292K |
Capital Lease Obligations | $345K |
Long Term Debt | - |
Current Long Term Debt | $32K |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $377K |
Other Current Liabilities | $525K |
Other Non Current Liabilities | - |
Total Shareholder Equity | $5.7M |
Treasury Stock | - |
Retained Earnings | -$25M |
Common Stock | $4.3K |
Common Stock Shares Outstanding | $3.1M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$4.6M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $343K |
Capital Expenditures | $604K |
Change In Receivables | - |
Change In Inventory | -$34K |
Profit Loss | - |
Cashflow From Investment | -$604K |
Cashflow From Financing | $5.8M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$6.1M |
Field | Value (USD) |
---|---|
Gross Profit | -$53K |
Total Revenue | $6.3K |
Cost Of Revenue | $59K |
Costof Goods And Services Sold | $59K |
Operating Income | -$6.2M |
Selling General And Administrative | $4.3M |
Research And Development | $1.8M |
Operating Expenses | $6.1M |
Investment Income Net | - |
Net Interest Income | -$58K |
Interest Income | - |
Interest Expense | $58K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $343K |
Income Before Tax | -$6.2M |
Income Tax Expense | -$137K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$6.1M |
Comprehensive Income Net Of Tax | - |
Ebit | -$6.1M |
Ebitda | -$5.8M |
Net Income | -$6.1M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Virax Biolabs Group Limited is a London-based biotechnology company dedicated to the prevention, detection, and management of viral diseases through cutting-edge diagnostic test kits and innovative medical technologies, including personal protective equipment (PPE). With a strong focus on immunology and a commitment to improving global healthcare outcomes, Virax is strategically positioned to address pressing public health challenges. The company aims to enhance its market presence while playing a crucial role in the global response to viral infections, making it a significant player in the biotechnology sector.